A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group,
multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple
Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with
cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function
(MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are
homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene
(F508del/F508del).